GenoMed Inc. (GMED)

[jmhollen]

from SI:

To:jmhollen who started this subject
From: gary schrimpf Monday, Jan 26, 2004 11:18 PM
Respond to of 93

From RB:
GMED Inflammation

I have only posted once here, but I have held GMED for many months. I am a member of the medical research establishment. In fact, I am preparing a paper for publication that may gain national attention in the area of infectious disease.

I came to GMED from quite a different route. I recently had a close family member who was dying of gastric cancer. In the last weeks of his life, I was feverishly researching each of his medical ailments in the hope that I could make him more comfortable or prolong his life. He began to get ascites: fluid filling his abdominal cavity. I pulled many papers on the treatment of malignant ascites. Most merely discussed regimens of paracentesis and intravascular fluid resuscitation -- pulling out the fluid with a needle and providing him with fluid in his veins to keep him from becoming hypotensive. However, a paper from England went into great detail about the use of ACE inhibitors. They claimed that the use of a prolonged regimen of such inhibitors of the renin-angiotensin system had reversed the collection of ascites in a significant number of patients. I was very perplexed. My relative died on the night before we could initiate the regimen, but I continued to ponder this finding. I went back to the textbooks, but I could find no reason for the effect of the ACE inhibitors. I began to search not only Medline but the standard internet search engines, and I found Dr. M and Genomedics. He, in my opinion, has the only cogent argument to explain the effects of ACE inhibitors on malignant ascites. I have followed the company closely since that time and am excited about the upcoming NIAID findings. It is also notable that the Malaysian partner appears to be funding research trials on Dr. M's postulates. This will have the same effect on GMED as a large cash investment directly from that partner; in fact, due to the present economic structure of research within the US, it is more cost effective.

Martin

http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=19736021